Pfizer and BioNTech achieved first authorization in the world for a vaccine to combat COVID-19
On Dec. 2, 2020, Pfizer and BioNTech announced that the Medicines & Healthcare Products Regulatory Agency (MHRA) in…
Pfizer and BioNTech submitted application for Conditional Marketing Authorization for COVID-19 vaccine
On Dec. 1, 2020, Pfizer and BioNTech announced they had submitted on Nov. 30, 2020, a formal Application…
City of Hope coronavirus vaccine produced strong immunity in preclinical research
On Nov. 30, 2020, the City of Hope reported that its investigational vaccine produced strong protective immunity against…
Moderna announced primary efficacy analysis in phase 3 COVE study for COVID-19 vaccine candidate
On Nov. 30, 2020, Moderna announced that the primary efficacy analysis of the Phase 3 study of mRNA-1273…
Novavax announced COVID-19 vaccine clinical development progress
On Nov. 30, 2020, Novavax announced that two of the three planned late-stage efficacy trials for NVX-CoV2373 sponsored…
Moderna amended supply agreement with UK Government for 2 million doses of mRNA COVID-19 vaccine
On Nov. 29, 2020, Moderna announced a supply agreement with the United Kingdom (UK) government for an additional…
Moderna announced EC approval of purchase agreement for 80 million doses of mRNA COVID-19 vaccine
On Nov. 25, 2020, Moderna announced that the European Commission (EC) has approved an agreement to secure 80…
BioNTech and Fosun Pharma announced start of phase 2 clinical trial of mRNA COVID-19 vaccine in China
On Nov. 25, 2020, BioNTech and Shanghai Fosun Pharmaceutica jointly announced that their lead mRNA COVID-19 vaccine candidate…
Roche announced FDA approval of Xofluza for prevention of influenza following contact with infected person
On Nov. 24, 2020, Roche announced that the U.S. Food and Drug Administration (FDA) had approved a supplemental…
NeuroRx and Relief announced successful results from expanded use of RLF-100 in patients with COVID-19
On Nov. 24, 2020, RELIEF THERAPEUTICS announced that more than 175 patients with Critical COVID-19 and Respiratory Failure…
MediciNova announced initiation of master virus seed stock production for intranasal COVID-19 vaccine
On Nov. 24, 2020, MediciNova announced development progress on its intranasal SARS-CoV-2 vaccine for COVID-19 utilizing BC-PIV, a…
Oxford University reported breakthrough on global COVID-19 vaccine
On Nov. 23, 2020, the University of Oxford, in collaboration with AstraZeneca, announced interim trial data from its…
AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19
On Nov. 23, 2020, AstraZeneca announced positive high-level results from an interim analysis of clinical trials of AZD1222…
Avian influenza virus spread rapidly in Europe
On Nov. 20, 2020, the ‘European Food Safety Authority reported that within the past month more than 300…
Oxford Coronavirus vaccine produced strong immune response in older adults
On Nov. 19, 2020, the University of Oxford announced that the ChAdOx1 nCov-2019 coronavirus vaccine had been shown…
Medigen Vaccines announced publication of positive results from preclinical studies of COVID-19 vaccine candidate
On Nov. 19, 2020, Medigen Vaccine Biologics announced that preclinical results of their COVID-19 vaccine candidate had been…
ApiJect approved for $590 million loan from US International DFC to build drug manufacturing facility in North Carolina
On Nov. 19, 2020, ApiJect Systems, a public benefit corporatio, announced that it had been approved by the…
Pfizer and BioNTech announced phase 3 study of COVID-19 vaccine candidate met all efficacy endpoints
On Nov. 18, 2020, Pfizer and BioNTech announced that, after conducting the final efficacy analysis in their ongoing…
CureVac established European-based network for manufacturing of COVID-19 vaccine candidate, CVnCoV
On Nov. 17, 2020, CureVac announced that it had accelerated the expansion of its manufacturing network to deliver…
Moderna announced supply agreement with UK Government to supply mRNA vaccine against COVID-19
On Nov. 17, 2020, Moderna announced a supply agreement with the government of the United Kingdom (UK) to…
Celdara Medical secured SBIR funding to develop an adjuvanted universal flu vaccine
On Nov. 17, 2020, Celdara Medical announced that the National Institute of Allergy and Infectious Disease (NIAID) of…
Wellcome Sanger Institute and COG-UK received £122M UK investment for COVID-19 genomic surveillance
On Nov. 16, 2020, the UK Department for Health and Social Care Testing Innovation Fund announced £12.2M funding…
Biological E Limited started phase I/II clinical trial of its COVID-19 vaccine candidate
On Nov. 16, 2020, Biological E. Limited (BE), a Hyderabad-based vaccines and pharmaceutical company, Dynavax Technologies, and Baylor…
Moderna announced longer shelf life for its COVID-19 vaccine candidate at refrigerated temperatures
On Nov. 16, 2020, Moderna announced new data showing that mRNA-1273, its COVID-19 vaccine candidate, remained stable at…
Tonix Pharmaceuticals reported positive immune response results from COVID-19 caccine candidate
On Nov. 16, 2020, Tonix Pharmaceuticals announced preliminary results following vaccination of non-human primates with TNX-1800 (modified horsepox…
BioNTech and Fosun Pharma approved to commence COVID-19 vaccine candidate BNT162b2 trial in China
On Nov. 16, 2020, BioNTech and Shanghai Fosun Pharmaceutica announced that the China National Medical Products Administration had…
INOVIO announced initiation of phase 2/3 clinical trial for COVID-19 DNA vaccine candidate, INO-4800
On Nov. 16, 2020, INOVIO announced that it had received clearance from the the U.S. Food & Drug…
European Medicines Agency began rolling review of Moderna’s mRNA vaccine candidate against COVID-19
On Nov. 16, 2020, Moderna announced that the European Medicines Agency (EMA) human medicines committee (CHMP) had started…
Johnson & Johnson Initiated second global phase 3 clinical trial of Janssen COVID-19 vaccine candidate
On Nov. 15, 2020, Johnson & Johnson announced that it continued to enroll and vaccinate study participants for…
Moderna’s COVID-19 vaccine candidate met primary endpoint in first interim analysis of phase 3 COVE study
On Nov. 15, 2020, an independent data and safety monitoring board (DSMB) overseeing the Phase 3 trial of…